Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

Annals of Hematology
Yeo-Kyeoung KimKorean Multiple Myeloma Working Party (KMMWP)

Abstract

The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment with bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11; cyclophosphamide 150 mg/m(2) orally on days 1-4; thalidomide 50 mg/day orally every day; and dexamethasone 20 mg/m(2) intravenously on days 1, 4, 8, and 11. The overall best response rate was 88%, with 46% complete response, 9% very good partial response, and 33% partial response. After a median follow-up of 12.6 months, the median progression-free survival (PFS) was 14.6 months with a 3-year PFS of 14% and the median overall survival (OS) was 31.6 months with a 3-year OS of 47%. Grade 3 or 4 adverse events included thrombocytopenia (12%), neutropenia (4%), peripheral sensory neuropathy (3%), with thrombosis being very rare (<1%). Bortezomib combined with cyclophosphamide, thalidomide, and dexamethasone is a highly effective salvage therapy with manageable toxicity for patients with relapsed or refractory multiple myeloma.

References

Feb 1, 1990·American Journal of Hematology·R AlexanianS Tucker
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosN Anagnostopoulos
Apr 18, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Ramón García-SanzJesús Fernando San Miguel
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Mar 20, 2004·Lancet·Bhawna Sirohi, Ray Powles
Oct 6, 2004·British Journal of Haematology·S JagannathK C Anderson
Oct 29, 2004·The New England Journal of Medicine·Robert A Kyle, S Vincent Rajkumar
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul G RichardsonAnthony A Amato
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Dec 7, 2006·Blood·Antonio PalumboUNKNOWN Gruppo Italiano Malattie Ematologicche dell'Adulto
Mar 6, 2007·Journal of the National Comprehensive Cancer Network : JNCCN·Paul G RichardsonKenneth C Anderson
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna E ReeceA Keith Stewart
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanPaul G Richardson
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Feb 3, 2009·British Journal of Haematology·Rakesh PopatJamie Cavenagh

❮ Previous
Next ❯

Citations

Nov 19, 2013·Annals of Hematology·Silvia ParkKihyun Kim
Apr 9, 2011·Case Reports in Oncology·Soo-Young BaeJe-Jung Lee
Sep 13, 2014·Hematology/oncology Clinics of North America·Silvia Gentili, Sagar Lonial
Dec 23, 2014·BioMed Research International·Jae-Sook AhnJe-Jung Lee
Jun 15, 2010·International Journal of Hematology·Jae Hoon LeeUNKNOWN Korean Multiple Myeloma Working Party
Apr 8, 2011·Expert Opinion on Investigational Drugs·Massimo OffidaniAntonio Palumbo
Feb 26, 2011·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·R Schots
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Dec 31, 2011·Clinical Lymphoma, Myeloma & Leukemia·Gerrard TeohYeo-Kyeoung Kim
Aug 7, 2010·Blood·A Keith Stewart
May 17, 2018·Expert Review of Anticancer Therapy·Giusy CetaniStefania Oliva
Jul 22, 2018·European Journal of Haematology·Evangelos TerposMeletios A Dimopoulos
Feb 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ali McBrideKeith Stockerl-Goldstein
Nov 14, 2012·Expert Review of Hematology·Ajay Nooka, Sagar Lonial
Jan 31, 2019·Health Science Reports·Cyrille HulinMichel Delforge
Sep 9, 2016·The Korean Journal of Internal Medicine·Junshik Hong, Jae Hoon Lee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.